
CLPT Stock Forecast & Price Target
CLPT Analyst Ratings
Bulls say
ClearPoint Neuro Inc. is positioned for a positive growth trajectory, demonstrating 17% topline growth in 2023 along with a significant reduction in cash burn, indicating improved profitability. The company's anticipation of over 20% revenue growth in 2024, supported by the expansion of its partnership base and higher value service offerings, reinforces its sustainable growth potential. Furthermore, momentum is bolstered by recent product approvals, record system installations, and supportive clinical publications, reducing regulatory risk and enhancing the overall outlook for the business.
Bears say
ClearPoint Neuro has demonstrated a significant reduction in cash burn, decreasing from $5.8 million in the first quarter of 2023 to $1.2 million by the fourth quarter, which signals improved cash management. Despite this positive trend, the ongoing reliance on cash conservation measures raises concerns regarding the company's operational sustainability and growth prospects. Furthermore, the financial metrics indicate potential underlying challenges in revenue generation or market demand, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.
CLPT Analyst Forecast & Price Prediction
Start investing in CLPT
Order type
Buy in
Order amount
Est. shares
0 shares